JP2008528702A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008528702A5 JP2008528702A5 JP2007554269A JP2007554269A JP2008528702A5 JP 2008528702 A5 JP2008528702 A5 JP 2008528702A5 JP 2007554269 A JP2007554269 A JP 2007554269A JP 2007554269 A JP2007554269 A JP 2007554269A JP 2008528702 A5 JP2008528702 A5 JP 2008528702A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- disease
- syndrome
- immune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 108090000623 proteins and genes Proteins 0.000 claims 15
- 208000026278 immune system disease Diseases 0.000 claims 14
- 102000004169 proteins and genes Human genes 0.000 claims 13
- 230000000694 effects Effects 0.000 claims 8
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims 7
- 239000003963 antioxidant agent Substances 0.000 claims 7
- 230000003078 antioxidant effect Effects 0.000 claims 7
- 210000002540 macrophage Anatomy 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 108010028771 Complement C6 Proteins 0.000 claims 3
- 102100024339 Complement component C6 Human genes 0.000 claims 3
- 101000596277 Homo sapiens TSC22 domain family protein 3 Proteins 0.000 claims 3
- 102100035260 TSC22 domain family protein 3 Human genes 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 230000037041 intracellular level Effects 0.000 claims 3
- 230000001629 suppression Effects 0.000 claims 3
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical group CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 claims 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 208000023328 Basedow disease Diseases 0.000 claims 2
- 102000008186 Collagen Human genes 0.000 claims 2
- 108010035532 Collagen Proteins 0.000 claims 2
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 claims 2
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 2
- 208000015023 Graves' disease Diseases 0.000 claims 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 2
- 208000007514 Herpes zoster Diseases 0.000 claims 2
- 201000011152 Pemphigus Diseases 0.000 claims 2
- 241000721454 Pemphigus Species 0.000 claims 2
- 208000031845 Pernicious anaemia Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 206010072148 Stiff-Person syndrome Diseases 0.000 claims 2
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 206010047124 Vasculitis necrotising Diseases 0.000 claims 2
- 206010047642 Vitiligo Diseases 0.000 claims 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 2
- 208000036923 autoimmune primary adrenal insufficiency Diseases 0.000 claims 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
- 229920001436 collagen Polymers 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 208000000509 infertility Diseases 0.000 claims 2
- 230000036512 infertility Effects 0.000 claims 2
- 231100000535 infertility Toxicity 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 2
- 201000003068 rheumatic fever Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 201000008827 tuberculosis Diseases 0.000 claims 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64925205P | 2005-02-02 | 2005-02-02 | |
| PCT/US2006/003973 WO2006084198A2 (en) | 2005-02-02 | 2006-02-02 | Nitroxides for use in treating or preventing immunological diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008528702A JP2008528702A (ja) | 2008-07-31 |
| JP2008528702A5 true JP2008528702A5 (https=) | 2008-11-13 |
Family
ID=36777997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007554269A Pending JP2008528702A (ja) | 2005-02-02 | 2006-02-02 | 免疫疾患の治療又は予防において使用するためのニトロキシド類 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20090209581A1 (https=) |
| JP (1) | JP2008528702A (https=) |
| WO (1) | WO2006084198A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2640738A1 (en) * | 2006-02-22 | 2007-09-07 | Othera Holding, Inc. | Hydroxylamines and derivatives for the inhibition of complement activation |
| CA2696310A1 (en) * | 2007-08-14 | 2009-02-19 | Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services, The | Method of treating disease involving myelin and/or axonal loss |
| CA2723118C (en) | 2008-05-02 | 2016-05-17 | University Of Tsukuba | Polymerized cyclic nitroxide radical compound and use thereof |
| RU2519140C1 (ru) * | 2013-03-11 | 2014-06-10 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Ростовский Государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО Рост ГМУ Минздрава России) | Способ лечения больных хроническими формами туберкулеза легких |
| CN107847484B (zh) * | 2015-03-26 | 2021-07-06 | 耶路撒冷希伯来大学伊森姆研究发展公司 | 用于治疗呼吸道疾病的硝基氧自由基 |
| US20180078539A1 (en) * | 2016-03-23 | 2018-03-22 | Louis Habash | T-cell regulation in t-cell mediated diseases by reducing pathogenic function of th17 in a human subject through treatment with a nitroxide |
| US10231959B2 (en) | 2016-03-23 | 2019-03-19 | Louis Habash | Increasing expression level of apoptosis-related genes by treating a human subject with a nitroxide |
| CN112426423B (zh) * | 2020-12-07 | 2021-12-14 | 首都医科大学附属北京妇产医院 | Tempol在制备治疗多囊卵巢综合征药物中的应用 |
| US12208089B2 (en) * | 2021-05-25 | 2025-01-28 | Louis Habash | Adjusting expression level of a gene encoding a Sirtuin protein by treating a human subject with a nitroxide |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0787492T3 (da) * | 1990-03-16 | 2004-02-02 | Us Secretary United States Dep | Anvendelse af nitroxider og oxazolidiner til beskyttelse mod ioniserende stråling og oxidativt stress |
| WO2002026231A1 (en) * | 2000-09-26 | 2002-04-04 | Georgetown University | Use of nitroxides for the treatment of vascular disorders in a diabetic mammal |
| US7285544B2 (en) * | 2003-11-18 | 2007-10-23 | Bernstein Eric F | Use of nitroxides in treating skin disease |
| JP2008528703A (ja) * | 2005-02-02 | 2008-07-31 | ミトス・ファーマシューティカルズ・インコーポレーテッド | アミロイド関連疾患の治療又は予防に用いるためのニトロキシド類 |
| US8563581B2 (en) * | 2005-02-02 | 2013-10-22 | Mitos Pharmaceuticals, Inc. | Nitroxides for use in treating predisposed or at risk patients |
-
2006
- 2006-02-02 US US11/815,441 patent/US20090209581A1/en not_active Abandoned
- 2006-02-02 JP JP2007554269A patent/JP2008528702A/ja active Pending
- 2006-02-02 WO PCT/US2006/003973 patent/WO2006084198A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018193377A5 (https=) | ||
| TNSN08505A1 (fr) | Compositions pharmaceutiques stabilisees comprenant de la fesoterodine | |
| JP2008528702A5 (https=) | ||
| JP2016512248A5 (https=) | ||
| JP2013147511A5 (https=) | ||
| HRP20151350T1 (hr) | Neuroprotekcija kod demijelinizacijskih bolesti | |
| JP2012031131A5 (https=) | ||
| JP2012031147A5 (https=) | ||
| WO2011106416A3 (en) | Abuse-resistant formulations | |
| JP2016530265A5 (https=) | ||
| TN2016000230A1 (en) | Orally disintegrating solid dosage unit containing an estetrol component. | |
| WO2011005811A8 (en) | Combination therapy for the treatment of diabetes | |
| JP2011518119A5 (https=) | ||
| JP2012524770A5 (https=) | ||
| WO2014058979A3 (en) | Laquinimod for reducing thalamic damage in multiple sclerosis | |
| JP2011527299A5 (https=) | ||
| WO2012090225A3 (en) | Novel cocrystals / molecular salts of metformin with oleoylethanolamide as an effective anti-diabetic + anti- obesity agent | |
| Selaković et al. | Second generation of diazachrysenes: Protection of Ebola virus infected mice and mechanism of action | |
| WO2008014361A3 (en) | Cyclic derivatives as modulators of chemokine receptor activity | |
| JP2017031105A5 (https=) | ||
| RU2009119567A (ru) | Уменьшение избыточной массы тела или ожирения | |
| WO2007121545A8 (en) | S-nitrosothiols containing compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions | |
| HRP20241042T1 (hr) | Novi analozi inzulina i njihova upotreba | |
| JP2008509939A5 (https=) | ||
| HRP20251123T1 (hr) | Ekopipam za liječenje touretteovog sindroma |